Dietressa®, a Drug Based on Antibodies to CB1 Cannabinoid Receptor, is a Novel Option for the Treatment of Obesity
N. N. Gurianova, J. L. Dugina, E. S. Zhavbert, O. I. Epstein
ООО «NPF «Materia Medica Holding», Moscow, Russia
Abstract
The preclinical and clinical trials of a novel drug containing ultra-low doses of antibodies to cannabioid receptor type 1 (Dietressa®) efficacy and safety in treating obesity are reviewed in the present paper. The effect of dietressa on the body weight gain in experimental animals on high-caloric diet comparable to that of sibutramine was shown. Dietressa also reduced the body mass of overweight patients and in patients with I and II stage obesity. Full toxicological and abuse potential study of dietressa revealed the safety of its use. No adverse events caused by dietressa were registered during the clinical studies. Key words: dietressa, cannabioid receptors, obesity.
Language: russian
Summary
N. N. Gurianova, J. L. Dugina, E. S. Zhavbert, O. I. Epstein
Dietressa®, a Drug Based on Antibodies to CB1 Cannabinoid Receptor, is a Novel Option for the Treatment of Obesity // Electronic periodical “Herald of the International Academy of Sciences. Russian Section”, 2012. #1